A new study that looked for relationships between early social media use and depression across adolescence and into young adulthood found that certain factors may make social media… read more.
Eisai Co. Ltd. and Biogen Inc. announced that that the FDA has accepted Eisai’s Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: Leqembi) intravenous (IV)… read more.
As described in research published in the Biotechnology Journal, investigators have developed a novel patch that can help liver tissue regenerate. The patch is a combination of decellularized liver… read more.
Fewer than one percent of people who get the flu every year get tested, in part because most tests require trained personnel and expensive equipment. Now researchers have… read more.
Aurinia Pharmaceuticals Inc. announced an oral presentation at the European Alliance of Associations for Rheumatology (EULA R) 2024 taking place in Vienna, Austria June 12-15. The data reinforces… read more.
Depressive symptoms are linked to subsequent memory decline in older people, while poorer memory is also linked to an increase in depressive symptoms later on, according to a… read more.
Targeted blood tests, asking patients about risk factors, and dose modifications can lessen the risk of potentially fatal reactions to antiseizure medications that millions of Americans take for… read more.
Ipsen announced that the FDA has granted accelerated approval for Iqirvo (elafibranor) 80 mg tablets for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid… read more.
A new study published in the International Journal of Eating Disorders found that mortality rates are high in patients with anorexia nervosa and nearly double in the presence of psychiatric… read more.
Results from a national survey indicate that many Americans, 61%, are unaware that primary care physicians can prescribe medications for opioid use disorder, and 13% incorrectly believed that they could… read more.
Bristol Myers Squibb announced that the European Commission (EC) has approved Opdivo (nivolumab) in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable… read more.
Roughly three times as many male athletes are banned for doping as female. A new doctoral thesis from Karolinska Institutet shows that one possible reason for this is… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
